Insmed, Inc. $INSM Position Decreased by Baker BROS. Advisors LP

Baker BROS. Advisors LP reduced its position in shares of Insmed, Inc. (NASDAQ:INSM) by 13.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,703,484 shares of the biopharmaceutical company’s stock after selling 1,009,416 shares during the period. Insmed makes up approximately 7.0% of Baker BROS. Advisors LP’s portfolio, making the stock its 4th largest position. Baker BROS. Advisors LP’s holdings in Insmed were worth $965,369,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Stone House Investment Management LLC purchased a new stake in Insmed in the 3rd quarter valued at approximately $29,000. SBI Securities Co. Ltd. increased its position in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in shares of Insmed by 59.6% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 81 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Insmed by 169.7% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 151 shares in the last quarter. Finally, RiverPark Advisors LLC acquired a new stake in shares of Insmed in the 3rd quarter valued at approximately $38,000.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $139.50 on Friday. The firm has a market capitalization of $30.07 billion, a price-to-earnings ratio of -21.76 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The business’s 50 day simple moving average is $155.18 and its 200-day simple moving average is $165.94. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business’s revenue for the quarter was up 152.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.32) earnings per share. As a group, equities analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on INSM shares. Wolfe Research set a $167.00 price target on Insmed and gave the company an “outperform” rating in a research note on Thursday, December 18th. Roth Mkm upgraded Insmed to a “strong-buy” rating in a research report on Friday, January 23rd. Barclays initiated coverage on Insmed in a report on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus set a $205.00 price target on shares of Insmed in a research note on Thursday, February 19th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $207.52.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 791 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.17, for a total value of $123,530.47. Following the completion of the transaction, the chief operating officer owned 106,810 shares in the company, valued at $16,680,517.70. This trade represents a 0.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $146.03, for a total value of $1,562,374.97. Following the completion of the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $43,982,045.55. This represents a 3.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 189,651 shares of company stock worth $31,784,545 over the last ninety days. 3.00% of the stock is currently owned by company insiders.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.